| First Author | Silvennoinen O | Year | 2015 |
| Journal | Cancer Cell | Volume | 28 |
| Issue | 1 | Pages | 1-2 |
| PubMed ID | 26175407 | Mgi Jnum | J:222996 |
| Mgi Id | MGI:5646313 | Doi | 10.1016/j.ccell.2015.06.010 |
| Citation | Silvennoinen O, et al. (2015) Targeting the Inactive Conformation of JAK2 in Hematological Malignancies. Cancer Cell 28(1):1-2 |
| abstractText | Activating JAK2 mutants cause hematological malignancies. Current clinical type I JAK2 inhibitors effectively relieve symptoms but fail to resolve the disease. In this issue of Cancer Cell, two articles by Wu and colleagues and Meyer and colleagues characterize a type II JAK2 inhibitor that is effective in preclinical models of JAK2-dependent myeloproliferative neoplasms and B cell acute lymphoblastic leukemia. |
